COMP <GO>
TMDX vs CBLL // ENTERPRISE SCALE & MARKET CAP
TransMedics Group Inc. (NASDAQ) VS. CeriBell Inc. (NASDAQ) • 15-METRIC TALLY: TMDX 7
— CBLL 3
▲ ENTERPRISE SCALE & MARKET CAP LEADER: TMDX
LAST: $65.99 (-1.68%) • MKT CAP: $2.33B
market-cap
$2.33B
LAST: $26.58 (-4.46%) • MKT CAP: $1.07B
market-cap
$1.07B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TMDX VS. CBLL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TMDX | CBLL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.90% | 87.90% | -28.00 | CBLL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.10% | -35.00% | +53.10 | TMDX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 14.6x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.74% | -3.89% | +9.63 | TMDX | /fcf-yield <GO> |
| Operating Margin | 17.90% | -60.00% | +77.90 | TMDX | /operating-margins <GO> |
| Net Profit Margin | 31.40% | -60.00% | +91.40 | TMDX | /net-margins <GO> |
| Revenue Growth (YoY) | 37.10% | 36.10% | +1.00 | TMDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.50 | 14.75 | -11.25 | CBLL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 4/9 | +4.00 | TMDX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.5 | 59.9 | -27.40 | CBLL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.2x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $2.33B | $1.07B | $1.26B | TMDX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TMDX REV | CBLL REV | TMDX GROSS % | CBLL GROSS % | TMDX FCF | CBLL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $605.5M | $89.1M | 59.9% | 87.9% | $133.6M | -$41.6M |
| FY 2024 | $441.5M | $65.4M | 59.4% | 86.7% | -$80.9M | -$36.4M |
| FY 2023 | $241.6M | $45.2M | — | — | -$13.0M | -$29.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TMDX // BETA —
CBLL // BETA —